Literature DB >> 24028351

Life on hold: the experience of living with neuromyelitis optica.

Kerry Mutch1, Abigail Methley, Phil Moore, Anu Jacob.   

Abstract

PURPOSE: Neuromyelitis optica (NMO) is a rare autoimmune condition characterised by acute relapses of optic neuritis and extensive transverse myelitis. The aim of this qualitative study was to develop an improved understanding of the experiences of people living with NMO.
METHOD: Fifteen participants completed a semi-structured interview and data were interpreted using a constant comparative method. Participants were recruited from the Northern UK NMO Service.
RESULTS: Five major themes were identified: diagnosis and treatment, symptoms, adjustment, identity and support.
CONCLUSION: Results suggest NMO is a difficult condition to live with due to the unpredictability of relapses and accrued disability of visual or spinal symptoms occurring with each relapse. Poor vision, reduced mobility, bladder dysfunction and pain affected participants' independence and experience of living with NMO. Participants reported that during relapse and recovery they would "put their life on hold". They identified the importance of periods of stability to enable them to adjust to their condition and therefore aim for "normality" of life that they believed was comparable to their peers. Implications for Rehabilitation Disability due to NMO has a major impact on an individual's life, abilities and identity. Timely treatment of relapse is essential to reduce or prevent disability. Health care professionals need to coordinate care locally and nationally. Multi-disciplinary work is vital to promote adjustment, coping strategies and support for people living with NMO.

Entities:  

Keywords:  Daily activities; lived experience; neuromyelitis optica; qualitative research; relapses

Mesh:

Year:  2013        PMID: 24028351     DOI: 10.3109/09638288.2013.833301

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  9 in total

Review 1.  Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder.

Authors:  Maureen A Mealy; Sharon L Kozachik; Michael Levy
Journal:  Pain Manag Nurs       Date:  2019-05-15       Impact factor: 1.929

Review 2.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

3.  Bevacizumab is safe in acute relapses of neuromyelitis optica.

Authors:  Maureen A Mealy; Kyong Shin; Gareth John; Michael Levy
Journal:  Clin Exp Neuroimmunol       Date:  2015-08-24

4.  Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.

Authors:  Maureen A Mealy; Audra Boscoe; Jaime Caro; Michael Levy
Journal:  Int J MS Care       Date:  2019 May-Jun

5.  Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica.

Authors:  Michael Levy; Maureen A Mealy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-04-24

6.  Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder.

Authors:  Jose E Meca-Lallana; Daniel Prefasi; Francisco Pérez-Miralles; Lucía Forero; María Sepúlveda; Carmen Calles; María L Martínez-Ginés; Inés González-Suárez; Sabas Boyero; Lucía Romero-Pinel; Ángel P Sempere; Virginia Meca-Lallana; Luis Querol; Lucienne Costa-Frossard; Hugo de Castro-Trapiello; Neus Canal; Jorge Maurino
Journal:  Patient Prefer Adherence       Date:  2021-04-12       Impact factor: 2.711

7.  Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.

Authors:  Chen Du; Pei Zeng; Jin-Rui Han; Tian-Xiang Zhang; Dongmei Jia; Fu-Dong Shi; Chao Zhang
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

8.  Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines.

Authors:  P Moore; C Jackson; K Mutch; A Methley; C Pollard; S Hamid; A Jacob
Journal:  BMJ Open       Date:  2016-09-30       Impact factor: 2.692

9.  Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study.

Authors:  Abigail M Methley; Kerry Mutch; Perry Moore; Anu Jacob
Journal:  Health Expect       Date:  2015-11-24       Impact factor: 3.377

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.